Skip to main content
Premium Trial:

Request an Annual Quote

Sanofi to Evaluate Hurel's Cell-based Technology for Drug Development

NEW YORK (GenomeWeb News) – Hurel today said that it has entered into a research and development collaboration with Sanofi to evaluate the use of Hurel's cell-based products and technologies for preclinical drug development.

The collaboration will take place in Hurel's laboratories in New Brunswick, NJ, and in Sanofi's R&D facilities in the US and Europe. The initial phase of the agreement will seek to validate Hurel's HurelHuman 3D liver tissue co-culture for use "across an array of experimental requirements" that usually are addressed during the preclinical phase of drug discovery and development, Hurel said.

Such applications include toxicological studies and studies of drug metabolism and pharmacokinetics. The HurelHuman in vitro liver construct uses a co-culture of primary cryopreserved human hepatocytes "to deliver highly sensitive and accurate predictions of the liver-mediated effects of drugs on humans," Hurel said.

Hurel and Sanofi plan to share results from the collaboration through co-authored, peer-reviewed scientific publications.

Further, the two companies plan to broaden the range of validated applications as part of the collaboration to include Hurel's HurelFlow microfluidic assay platform.

Financial and other terms were not disclosed.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.